Sign In
|
Register
|
About San Anselmo
|
Contact Us
San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast
|
Traffic
San Anselmo News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
San Anselmo Gas Prices
Ski And Snow Reports
Financial Markets
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Attractions
Antiques
Nightlife
Family Activities
Arts & Culture
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Apartment Finding & Rentals
Apartments
Senior Apartments
Art & Culture
Galleries & Dealers
Museums
Theatres
Associations, Foundations and Organizations
Business & Professional Clubs
Chambers of Commerce
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Sales Organizations
Attractions & Entertainment
Amusement & Water Parks
Galleries
General Attractions
Museums
Parks & Preserves
Theatre
Automotive
Dealers - Antique & Classic
Dealers - New
Dealers - Used
Motorcycles
Parts & Supplies
Repair & Service
Beauty & Fitness
Barbers
Beauty Salons
Dance Clubs & Studios
Fitness Programs
Health Clubs & Gyms
Massage
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business Legal Services
Communications Services
Computer & Audio Visual Services
Consultants
Copier & Fax Services, Equipment
Data Processing Service
Durable Goods
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Management Services
Marketing & Advertising Services
Media Services
Office Furniture, Equipment & Supplies
Photography
Printing & Publishing
Public Relations & Publicity
Research
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Telecommunications
Trucking & Hauling
Video Production
Commercial Contractors
Concierge & Lifestyle Services
Contractors
Architects
Building Contractors & Consultants
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Pet Sitting and Day Care
Education
Art Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Middle Schools
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Appraisers
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Misc. Financial Services
Mortgage Lenders
Personal
Government
Post Offices
Health and Medicine
Alternative Medicine / Acupuncture
Animal Health
Chiropractors
Counseling
Dentistry
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Massage
Medical Doctors
Mental Health
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Accessories
Bed & Bath
Cabinets, Racks & Shelves
Carpets & Rugs
Cleaning Supplies & Services
Contractors
Electric
Floor Coverings
Furniture
Heating, Cooling & AC
Home Improvement Centers
Kitchen
Lamps & Lighting
Lawn & Garden
Masonry & Stone Work
Nurseries & Garden Centers
Painting & Wallcoverings
Plumbing
Tree Services
Insurance
Agents & Brokers
Auto
Health
Home
Life
Pets
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Food & Beverage
Media
Cable & Pay TV Services
Print Publications
Television Stations
Meeting & Event Planning
Audio & Visual
Event Facilities
Exhibit Designers
Lodging
Meeting Planners
Party Rentals & Entertainment
Travel Arrangement & Services
Miscellaneous
Nightlife
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Personal Service
Barbers, Beauty Salons & Spas
Shoe Repair
Pets
Pet Shops
Training
Veterinary Hospitals
Real Estate
Appraisers
Commercial
Condominiums
Developers
Mortgage Lenders
Property Management
Real Estate Agents and Brokers
Residential
Religion
Relocation
Movers
Storage
Restaurants
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Shopping
Accessories
Antiques
Books
Bridal Shops
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Convenience Stores
Department Stores
Discount Stores
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Gourmet & Specialty Foods
Grocery Stores
Health Food Stores
Home Improvement
Indian Arts & Crafts - Retail
Jewelry
Men's Clothing Stores
Notions
Office Supplies & Service
Pharmacies
Repair Shops
Resale Shops
Shoe Stores
Sporting Goods
Thrift Stores
Videos
Women's Clothing Stores
Spas
Beauty Salons
Sports & Recreation
Bicycles
Dance Clubs & Studios, Instruction
Health Clubs
Instruction
Recreation Facilities
Sporting Goods
Technology
Communications
Computer Maintenance and Repair
Computer Services & Consultants
E-commerce
Internet Advertising & Services
Semiconductor
Software
Web Design
Web Development
Travel & Transportation
Hotels & Resorts
Taxi, Limousine & Shuttle
Travel Agencies
Weddings
Bridal Shops
Entertainment
Florists
Health & Beauty
Photographers & Videographers
Apartments
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in San Anselmo
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
October 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
October 07, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Hold Investor Event on November 16
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases
September 30, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
September 27, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
September 20, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma whose Tumors Express PD-L1 with CPS ≥ 5
September 17, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
September 16, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
According to New Multinational Survey, Healthcare Providers Believe Immunotherapy Has Potential to Positively Impact Earlier-Stage Cancer Treatment Landscape Across Tumor Types
September 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial
September 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Shares Research Supporting Correlation Between New York Heart Association Functional Class (NYHA class) and Mortality in Obstructive Hypertrophic Cardiomyopathy
September 10, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
September 09, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021
September 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers
September 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride
September 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare Conference
September 07, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)
August 23, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma
August 20, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma
August 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
August 17, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry
August 10, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland
August 03, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
July 30, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
July 28, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
July 16, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy
June 29, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
June 25, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma
June 25, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
San Anselmo
|
San Anselmo News
|
San Anselmo Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Calendar
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.